Home/Pipeline/Aerosolized Platinum Nanoparticles

Aerosolized Platinum Nanoparticles

Lung Cancer

Pre-clinicalActive

Key Facts

Indication

Lung Cancer

Phase

Pre-clinical

Status

Active

Company

HylaPharm

About HylaPharm

HylaPharm is a private, preclinical-stage biotech leveraging a proprietary hyaluronan-based nanoconjugate platform for localized drug delivery. The company's lead programs focus on intratumoral delivery of chemotherapeutics (like cisplatin) and immunomodulators to stimulate anti-tumor immunity, with compelling proof-of-concept data from spontaneous canine cancer models. Its dual strategy targets the significant unmet need in human immuno-oncology, where many patients are resistant to checkpoint inhibitors, while also addressing the veterinary oncology market. The company has been funded through SBIR grants and angel investment.

View full company profile

Therapeutic Areas

Oncology

Other Lung Cancer Drugs

Drug	Company	Phase	Status
15dPMJ2	Claradele Pharmaceuticals	Research	Exploratory (Pathway Implied)
SUPLEXA	Alloplex Biotherapeutics	Phase 1	Completed
Oncology Digital Biomarkers	Imvaria	Development	Active
ENV105	Kairos Pharma	Phase 1	Active
AI for Lung Cancer	Invenio Imaging	Research	Active
Liposome Program	NanoTech Pharma	Preclinical/Phase 1/2	Active
Dendritic Cell Vaccine	MegaNano BioTech	Pre-clinical	Active
Aiforia® Lung Cancer Suite	Aiforia Technologies	Approved	Active
AI Biomarkers for Lung Cancer	BioAI Health	Unknown	Active
PRDM2 Target	ARIZ Precision Medicine	Preclinical	Active
ZEN-3694	Zenith Epigenetics	Proof-of-Concept	Active
TEC-001 + Keytruda	Teclison	Phase 2	Active